Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Sell
26
AMGN Quote, Financials, Valuation and Earnings
Last price:
$275.89
Seasonality move
:
8.91%
Day range:
$268.81 - $277.61
52-week range:
$253.30 - $346.85
Dividend yield:
3.38%
P/E ratio:
24.68x
P/S ratio:
4.29x
P/B ratio:
23.43x
Volume:
3.2M
Avg. volume:
3.1M
1-year change:
-9.7%
Market cap:
$145.4B
Revenue:
$33.4B
EPS (TTM):
$10.96
Analysts' Opinion
-
Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating is a Hold based on 9 Buy ratings, 15 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $313.62, Amgen has an estimated upside of 15.97% from its current price of $270.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $185.00 representing 31.59% downside risk from its current price of $270.44.
Fair Value
-
According to the consensus of 26 analysts, Amgen has 15.97% upside to fair value with a price target of $313.62 per share.
AMGN vs. S&P 500
-
Over the past 5 trading days, Amgen has underperformed the S&P 500 by -6.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Amgen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amgen has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Amgen reported revenues of $8.1B.
Earnings Growth
-
Amgen earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Amgen reported earnings per share of $3.20.
Enterprise value:
194B
EV / Invested capital:
3.05x
Price / LTM sales:
4.29x
EV / EBIT:
19.99x
EV / Revenue:
5.68x
PEG ratio (5yr expected):
0.44x
EV / Free cash flow:
17.77x
Price / Operating cash flow:
13.41x
Enterprise value / EBITDA:
12.69x
Gross Profit (TTM):
$21.5B
Return On Assets:
6.51%
Net Income Margin (TTM):
17.39%
Return On Equity:
97.08%
Return On Invested Capital:
8.85%
Operating Margin:
14.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $26.2B | $29.5B | $34.1B | $7.4B | $8.1B | |
| Gross Profit | $19.6B | $19.6B | $21.5B | $4.2B | $5.2B | |
| Operating Income | $9B | $7B | $7.4B | $991M | $1.2B | |
| EBITDA | $14.2B | $12.1B | $15.3B | $2.2B | $4.1B | |
| Diluted EPS | $14.71 | $7.00 | $10.96 | -$0.21 | $3.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.3B | $18.5B | $44.7B | $28B | $26.9B | |
| Total Assets | $62.5B | $59.2B | $88.7B | $93B | $89.4B | |
| Current Liabilities | $12.9B | $12.9B | $14.2B | $19.7B | $23B | |
| Total Liabilities | $53.2B | $58.3B | $83.4B | $88B | $83.2B | |
| Total Equity | $9.3B | $916M | $5.3B | $5B | $6.2B | |
| Total Debt | $32.7B | $36.9B | $61.6B | $64B | $57.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8.6B | $8.1B | $12.2B | $689M | $1.4B | |
| Cash From Investing | -$4.6B | -$27.8B | -$1.3B | -$217M | -$447M | |
| Cash From Financing | $21B | -$2.2B | -$11.8B | -$1.7B | -$4.1B | |
| Free Cash Flow | $7.5B | $7.1B | $10.9B | $459M | $980M | |
AMGN
Sector
Market Cap
$145.4B
$34.5M
Price % of 52-Week High
77.97%
43.57%
Dividend Yield
3.38%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
-9.7%
-42.08%
Beta (5-Year)
0.502
0.660
Dividend yield:
3.38%
Annualized payout:
$9.00
Payout ratio:
82.64%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$282.36
200-day SMA
Sell
Level
$303.35
Bollinger Bands (100)
Sell
Level
269.26 - 306.3
Chaikin Money Flow
Buy
Level
178.9M
20-day SMA
Sell
Level
$282.83
Relative Strength Index (RSI14)
Sell
Level
35.49
ADX Line
Sell
Level
28.69
Williams %R
Buy
Level
-92.6095
50-day SMA
Sell
Level
$299.52
MACD (12, 26)
Sell
Level
-5.29
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
184.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2768)
Sell
CA Score
(Annual)
Level (-1.9578)
Buy
Beneish M-Score
(Annual)
Level (-2.8424)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.4355)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Stock Forecast FAQ
In the current month, AMGN has received 9 Buy ratings 15 Hold ratings, and 2 Sell ratings. The AMGN average analyst price target in the past 3 months is $313.62.
-
Where Will Amgen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amgen share price will rise to $313.62 per share over the next 12 months.
-
What Do Analysts Say About Amgen?
Analysts are divided on their view about Amgen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amgen is a Sell and believe this share price will drop from its current level to $185.00.
-
What Is Amgen's Price Target?
The price target for Amgen over the next 1-year time period is forecast to be $313.62 according to 26 Wall Street analysts, 9 of them rate the stock a Buy, 2 rate the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is AMGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amgen is a Hold. 15 of 26 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMGN?
You can purchase shares of Amgen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amgen shares.
-
What Is The Amgen Share Price Today?
Amgen was last trading at $275.89 per share. This represents the most recent stock quote for Amgen. Yesterday, Amgen closed at $270.44 per share.
-
How To Buy Amgen Stock Online?
In order to purchase Amgen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
